表紙
市場調査レポート

世界おける非ホジキンリンパ腫治療市場

Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 307327
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界おける非ホジキンリンパ腫治療市場 Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018
出版日: 2014年06月30日 ページ情報: 英文 91 Pages
概要

世界の非ホジキンリンパ腫治療市場は、2013年から2018年にかけて、7.03%のCAGRで拡大することが見込まれています。

当レポートでは、世界における非ホジキンリンパ腫治療市場の現状と将来の見通し、エンドユーザー別、地域別の動向、市場の成長因子と課題、主要ベンダーのプロファイルなどを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品
    • 製品プロファイル

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 罹患率と有病率

第8章 治療タイプ別の市場区分

  • 化学療法
  • 標的療法

第9章 パイプラインポートフォリオ

第10章 地理区分

第11章 購入基準

第12章 市場成長因子

第13章 成長因子とその影響

第14章 市場の課題

第15章 成長因子と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
  • その他の有力ベンダー

第19章 主要ベンダーの分析

  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline plc

第20章 関連レポート

目次
Product Code: IRTNTR3709

About Non-Hodgkin Lymphoma (NHL) and its Diagnostic Procedures

Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests.

TechNavio's analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.

TechNavio's report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bristol Myers Squibb Co.
  • Celgene Corp.
  • Eli Lilly and Co.
  • F. Hoffman La-Roche Ltd.
  • GlaxoSmithKline plc

Other Prominent Vendors

  • Accredo Health Group Inc.
  • Baxter International Inc.
  • Bayer AG
  • Cephalon Inc.
  • Eisai Pharmaceuticals Inc.
  • Genelabs Technologies Inc.
  • Hospira Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Millenium Pharmaceuticals Inc.
  • Pacira Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Inc.

Key Market Driver

  • Availability of Biosimilars at a Reduced Price.

For a full, detailed list, view our report.

Key Market Challenge

  • High Cost of NHL Drugs.

For a full, detailed list, view our report.

Key Market Trend

  • Dominance of NHL Market by Biologics.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

  • 08.1.1. Chemotherapy
  • 08.1.2. Targeted Therapy

09. Pipeline Portfolio

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Bristol-Myers Squibb Co.
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Product Segmentation
    • 19.1.4. Sales by Geography
    • 19.1.5. Business Strategy
    • 19.1.6. Key Information
    • 19.1.7. SWOT Analysis
    • 19.1.8. Strengths
    • 19.1.9. Weaknesses
    • 19.1.10. Opportunities
    • 19.1.11. Threats
  • 19.2. Celgene Corp.
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Strategy
    • 19.2.4. Business Segmentation by Revenue 2011-2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Key Developments
    • 19.2.7. SWOT Analysis
    • 19.2.8. Strengths
    • 19.2.9. Weaknesses
    • 19.2.10. Opportunities
    • 19.2.11. Threats
  • 19.3. Eli Lilly and Co.
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis
    • 19.3.9. Strengths
    • 19.3.10. Weaknesses
    • 19.3.11. Opportunities
    • 19.3.12. Threats
  • 19.4. F. Hoffmann La Roche Ltd.
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Sales by Geography
    • 19.4.6. Business Strategy
    • 19.4.7. Key Information
    • 19.4.8. SWOT Analysis
    • 19.4.9. Strengths
    • 19.4.10. Weaknesses
    • 19.4.11. Opportunities
    • 19.4.12. Threats
  • 19.5. GlaxoSmithKline plc
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Sales by Geography
    • 19.5.6. Pipeline Products
    • 19.5.7. Business Strategy
    • 19.5.8. Key Information
    • 19.5.9. SWOT Analysis
    • 19.5.10. Strengths
    • 19.5.11. Weaknesses
    • 19.5.12. Opportunities
    • 19.5.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Non-Hodgkin Lymphoma therapeutics market (in US$ billions)
  • Exhibit 3: Global Non-Hodgkin Lymphoma Therapeutics Market by Type of Therapy
  • Exhibit 4: Pipeline Portfolio of Global Non-Hodgkin Lymphoma Therapeutics Market
  • Exhibit 5: Global NHL Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
  • Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
  • Exhibit 8: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 9: Celgene Corp.: Sales by Geography 2013
  • Exhibit 10: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 11: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 12: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 17: GlaxoSmithKline Plc: Business Segmentation 2013
  • Exhibit 18: GlaxoSmithKline Plc: Business Segmentation by Revenue 2012 and 2013 (in US$ billion)
  • Exhibit 19: GlaxoSmithKline Plc: Sales by Geography 2013
  • Exhibit 20: GlaxoSmithKline plc: Pipeline Products 2013
Back to Top